Jupiter Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.25 Cr
- Paid Up Capital ₹ 1.01 Cr
- Company Age 48 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.06 Cr
- Satisfied Charges ₹ 11.67 Cr
- Revenue Growth 7.97%
- Profit Growth -7.09%
- Ebitda 6.37%
- Net Worth 21.73%
- Total Assets 20.73%
About Jupiter Pharmaceuticals
Jupiter Pharmaceuticals Ltd (JPL) is a leading Public Limited Indian Non-Government Company incorporated in India on 28 October 1976 and has a history of 48 years and three months. Its registered office is in 24 Parganas, West Bengal, India.
The Corporate was formerly known as Jupiter Pharmaceuticals Pvt Ltd. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.25 Cr and a paid-up capital of Rs 1.01 Cr.
The company currently has active open charges totaling ₹5.06 Cr. The company has closed loans amounting to ₹11.67 Cr, as per Ministry of Corporate Affairs (MCA) records.
Gour Sarkar, Shyamasree Sarkar, and Mriganka Sarkar serve as directors at the Company.
Company Details
- Location
24 Parganas, West Bengal, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24239WB1976PLC030746
- Company No.
030746
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
28 Oct 1976
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
What products or services does Jupiter Pharmaceuticals Ltd offer?
Jupiter Pharmaceuticals Ltd offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Medicine, Ear Drops, Nutraceuticals & Dietary Supplements, Mineral Supplement, Ayurvedic,Herbal Products & Medicine, Ayurvedic Pain Relief Oil.
Who are the key members and board of directors at Jupiter Pharmaceuticals?
Executive Team (1)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Mriganka Sarkar ![]() | Managing Director | 22-Mar-2007 | Current |
Board Members (2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Gour Sarkar ![]() | Director | 28-Oct-1976 | Current |
Shyamasree Sarkar ![]() | Director | 28-Aug-2014 | Current |
Financial Performance of Jupiter Pharmaceuticals.
Jupiter Pharmaceuticals Ltd, for the financial year ended 2023, experienced modest growth in revenue, with a 7.97% increase. The company also saw a slight decrease in profitability, with a 7.09% decrease in profit. The company's net worth Soared by an impressive increase of 21.73%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Jupiter Pharmaceuticals?
In 2022, Jupiter Pharmaceuticals had a promoter holding of 62.05% and a public holding of 37.96%. The company had 2 Associate Companies. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Charges (Loans)
₹5.06 Cr
₹11.67 Cr
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 5.00 Cr
- Ge Capital Transportation Financial Services Ltd : 0.06 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
27 Nov 2012 | Axis Bank Limited | ₹5.00 Cr | Open |
27 Jun 2007 | Ge Capital Transportation Financial Services Ltd | ₹0.55 M | Open |
24 Feb 2022 | Axis Bank Limited | ₹3.48 Cr | Satisfied |
11 Apr 2015 | Axis Bank Limited | ₹3.97 Cr | Satisfied |
27 Oct 2006 | State Bank Of India | ₹1.50 Cr | Satisfied |
How Many Employees Work at Jupiter Pharmaceuticals?
Jupiter Pharmaceuticals has a workforce of 202 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Jupiter Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jupiter Pharmaceuticals's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.